Studies on Haemato- Biochemical Changes and Evaluation of Combination Therapy Against B. gibsoni

Narayani Yadav; Debabrata Mondal; R. Raguvaran; Arvind Kumar Das; Dushyant Kumar Sharma; Abhishek Chandra Saxena

doi:10.5455/ijlr.20200922122528

Authors

Narayani Yadav PhD Scholar, Division of Medicine, IVRI, Izatnagar, Bareilly, Uttar Pradesh, INDIA
Debabrata Mondal Principal Scientist, Division of Medicine, IVRI, Izatnagar, Bareilly, Uttar Pradesh, INDIA
Raguvaran R Scientist, Division of Medicine, IVRI, Izatnagar, Bareilly, Uttar Pradesh,
Arvind Kumar Das PhD Scholar, Division of Medicine, IVRI, Izatnagar, Bareilly, Uttar Pradesh, INDIA
Dushyant Kumar Sharma PhD Scholar, Division of Medicine, IVRI, Izatnagar, Bareilly, Uttar Pradesh, INDIA
Abhishek Chandra Saxena Scientist, Division of Surgery, IVRI, Izatnagar, Bareilly, Uttar Pradesh, INDIA

DOI:

https://doi.org/10.5455/ijlr.20200922122528%20%20%20%20%20

Keywords:

Babesia, Canine, Clindamycin, Doxycycline, Metronidazole, Therapy

Abstract

Babesiosis is one of the main causes of anemia in dogs and lot of research has been proposed for its pathogenesis. Present study was envisaged to study the hemato-biochemical changes with different therapeutic interventions against Babesia gibsoni in canines. During the study period, 2236 dogs were presented to TVCC, IVRI, of which 48 dogs were suspected for hemoprotozoan diseases and finally 15 dogs were found positive for B. gibsoni by microscopic examination. Blood samples were taken to study hematological and serum changes. Positive dogs were randomly divided into 3 groups (n=5) for different therapeutic interventions. Dogs of Gr. I received Berenil (5mg/Kg IM) and was repeated after 7 days. Dogs of Gr. II were treated with combination of Doxycycline @ 10mg/Kg PO q12h and Clindamycin @ 25mg/Kg q12h for 21 days. Dogs of Gr. III received combination of Doxycycline @ 10mg/Kg q12h, Clindamycin @25mg/Kg q12h, Metronidazole @ 7mg/Kg q12h for 21 days. All the treated dogs received need based supportive therapy in addition to the specific therapy.

References

Abdullahi, S.U., Mohammed. A.A., Trimnell, A.R., Sannusi. A. and Alafiatayo. R. (1990). Clinical and haematological findings in 70 naturally occurring cases of canine babesiosis. J. Small Anim. Pract. 31, 145-147.

Beugnet, F., Moreau, Y. (2015). Babesiosis. Rev. Sci. Tech. 34, 627–639

Bhataia, B, B., Pathak, K, M. L. and Juyal, P.D. (2000). Text book of Veterinary Parasitology, Kalyani Publisher, 289-311.

Bick, R.L. Arun, B. and Frenkel, E.P. (1999). Disseminated intravascular coagulopathy: clinical and pathophysiological mechanism and manifestations. Hemostasis, 29, 111- 134.

Boozer, L. and Macintire, D. (2005). Babesia gibsoni: An Emerging Pathogen in Dogs. Compendium, Article 2. Auburn University. 33-42.

Ettinger. S.J. and Feldman, E.C. (2000). Text book of veterinary internal medicine: Disease of dog and cat. Philadelphia: W.B. Saunders Co 7th Ed., Elseiver, 916-917.

Irwin, P.J. (2009). Canine babesiosis: from molecular taxonomy to control. Parasit. 2, S4

Islam, S., Kalita, D and Dutta, T.C. (2017). Comparative efficacy of combination therapeutics for management of canine babesiosis. Intas Polivet, 19.

Jacobson, L.S and Clark, I.A. 1994. Review/Oorsig. The pathophysiology of canine babesiosis: new approaches to an old puzzle. J. South African Vet. Assoc, 65, 134-145.

Jefferies, R., Ryan, U.M., Jardine, J., Robertson, I.D., Irwin, P.J. (2007b). Babesia gibsoni: detection during experimental infections and after combined atovaquone and azithromycin therapy. Exp. Parasitol, 117, 115–123.

Kirk, S.K., Levy, J.K., Crawford, P.C. (2017). Efficacy of azithromycin and compounded atovaquone for treatment of in dogs. J. Vet. Intern. Med. http://dx.doi.org/10.1111/jvim.14777

Lin, E.C., Chueh, L.L., Lin, C.N., Hsieh, L.E., Su, B.L. (2012). The therapeutic efficacy of two antibabesial strategies against Babesia gibsoni. Vet. Parasitol, 186, 159–164.

Murase, T, Ueda, T., Yamato, O., Tajima, T., Maede, Y. (1996). Oxidative damage and enhanced erythrophagocytosis in canine erythrocytes infected with Babesia gibsoni. Journal of Veterinary Medical Science, 58, 259-261.

Solano-Gallego, L., Baneth, G. (2011). Babesiosis in dogs and cats–expanding parasitological and clinical spectra. Vet. Parasitol, 181, 48–60.

Strombeck, D.R. and Gribble, D. (1978). Chronic active hepatitis in the dog. J. Am. Vet. Med. Assoc. 173, 380-386.

Van mourik, J.A. Romani de wit, T. (2001). Von wiilebrand factor propeptide in vascular disorders. Thromb haemostat, 86, 164-71.

Vial, H.J. and Gorenflot, A. (2006). Chemotherapy against babesiosis. Vet. Parasitol, 138, 147–160.

Welzl C, Leisewitz A.L, Jacobson, L.S., Vaughan-Scott, T., Myburgh, E. (2000). Systemic inflammatory response syndrome and multiple-organ damage/ dysfunction in complicated canine babesiosis. J S Afr Vet Assoc, 72, 158–162.